美国食品药品监督管理局（FDA）已正式批准泰诺®与萘普生复方制剂上市。这款产品是首款且唯一一款非处方固定剂量组合药物，其成分为对乙酰氨基酚（650毫克）与萘普生钠（220毫克）。
美国食品药品监督管理局（FDA）已正式批准泰诺®与萘普生复方制剂上市。这款产品是首款且唯一一款非处方固定剂量组合药物，其成分为对乙酰氨基酚（650毫克）与萘普生钠（220毫克）。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.